Relevant events up to December 31st, 2019
GRIFOLS, S.A. guarantees that the texts published in this page correspond exactly and entirely with the texts sent to the CNMV by the Company or by third parties. All the communications are available in the Web page of the CNMV.
2019
December 6, 2019
Grifols presents its latest Alzheimer's clinical trial data
November 20, 2019
Payment details of the interim dividend on account of 2019 earnings
October 31, 2019
Grifols approves the payment of an interim dividend on account of 2019
October 29, 2019
Grifols increases its revenues by 14.5% to EUR 3,738 million
October 28, 2019
Grifols to initiate secured debt-refinancing for an amount of EUR 5,300 million
July 16, 2019
Grifols presents additional encouraging Alzheimer's trial results
May 2, 2019
Grifols expands its plasma collection network by acquiring IBBI
April 16, 2019
Notice of Annual General Shareholders' Meeting 2019
March 29, 2019
Grifols presents additional results of its AMBAR clinical trial to treat Alzheimer´s
March 7, 2019
Grifols enters a strategic alliance with Shanghai RAAS in China
2018
December 18, 2018
Change of category of Mr. Ramón Riera Roca
November 23, 2018
Payment details of the interim dividend on account of 2018 earnings
November 21, 2018
Grifols enters talks with Shanghai RAAS regarding a possible investment
November 2, 2018
Grifols approves the payment of an interim dividend on account of 2018
October 3, 2018
Response to recent published research
June 4, 2018
Grifols closes the acquisition of Haema AG
April 20, 2018
Notice of Annual General Shareholders' Meeting 2018
February 23, 2018
Appointment of new Chairperson of the Audit Committee
January 30, 2018
Impact of the U.S. tax reform and other non-recurring items
January 26, 2018
Grifols acquires a 51% in the U.S. technology firm MedKeeper for USD 98 million
2017
November 16, 2017
Payment details of the interim dividend on account of 2017 earnings
November 6, 2017
FDA approves a new Grifols product, fibrin sealant ("Fibrin Sealant")
October 30, 2017
The Board of Directors approves an interim dividend on account of 2017 results
July 25, 2017
Grifols announces the acquisition of an additional 40% equity stake in Kiro Grifols
July 5, 2017
Grifols acquires a 44% shareholding in GigaGen
June 7, 2017
Manufacturing and supply agreement
April 21, 2017
Notice of Annual General Shareholders' Meeting 2017
April 6, 2017
Communication to the Irish Stock Exchange
March 20, 2017
Communication to the Irish Stock Exchange
February 6, 2017
Grifols has concluded the refinancing process of part of its financial debt
January 31, 2017
Grifols closes the acquisition of Hologic's share of NAT donor screening unit
January 12, 2017
Grifols to acquire the 49% in Access Biologicals
2016
November 21, 2016
Details of the interim dividend payment on account of 2016 earnings
October 7, 2016
The United States Department of Justice closes its inquiry into Grifols
April 22, 2016
Notice of Annual General Shareholders' Meeting 2016
April 8, 2016
Agreements signed to acquire a 49% stake in IBBI
March 8, 2016
Industrial investments plan 2016-2021 for the Bioscience division
2015
December 14, 2015
The Board of Directors approves the Succession Plan of Grifols
December 3, 2015
Grifols announces a stock split of the company's shares
November 30, 2015
Details of payment of interim dividend on account of 2015 profit
October 28, 2015
Grifols agrees long term loan with the European Investment Bank
October 26, 2015
Payment of interim dividend on account of 2015 profit
April 24, 2015
Notice of Annual General Shareholders' Meeting 2015
2014
November 26, 2014
Payment of interim dividend on account of 2014 profit
November 17, 2014
Grifols receives FDA approval for its new fractionation plant in Clayton
September 19, 2014
Grifols subscribes to a capital increase of the company Kiro Robotics, S.L.
May 29, 2014
Senior Unsecured notes admitted to listing in the Irish Stock Exchange
April 25, 2014
Notice of Annual General Shareholders' Meeting 2014
April 4, 2014
Grifols opens new plasma fractionation plant in Spain (Press release)
March 17, 2014
Grifols has concluded the refinancing process of its debt
March 6, 2014
Grifols issues $1billion senior unsecured notes
February 24, 2014
Grifols starts the refinancing process
February 24, 2014
Appointment of new president of the Audit Committee
January 10, 2014
Grifols closes the acquisition of Novartis AG diagnostic business unit
Previous
2013
November 15, 2013
Notice of Extraordinary General Shareholders' Meeting December 2013
November 11, 2013
Grifols to acquire Novartis diagnostics business unit for US$1,675 million
August 28, 2013
Grifols informs of the closing of the subscription of the shares of Aradigm Corp
April 22, 2013
Notice of Annual General Shareholders' Meeting 2013
April 19, 2013
New non-voting class B shares admitted to listing
March 12, 2013
Grifols purchases ADRs from Cerberus'
January 11, 2013
New non-voting class B shares admitted to listing
2012
December 10, 2012
Announcement of Grifols S.A Share Capital Increase
October 29, 2012
Notice of Extraordinary General Shareholders' Meeting December 2012
September 19, 2012
CNMV Communications
August 1, 2012
Standar & Poor´s: Rating upgrade
July 23, 2012
ADS's Exchange Ratio Modification
July 9, 2012
Grifols informs that Moody's Investors Services has upgraded its ratings
2011
December 29, 2011
New non-voting class B shares admitted to listing in Spain Download (70,95 Kb)
December 5, 2011
Announcement of Grifols S.A Share Capital Increase
November 8, 2011
3Q results reporting date postponed
October 28, 2011
Notice of Extraordinary General Shareholders' Meeting December 2011
June 3, 2011
Execution of the agreement with Kedrion
June 2, 2011
Closing of the acquisition of Talecris Biotherapeutics
June 1, 2011
Changes in the board of directors
May 24, 2011
Information on the resolutions approved at the Ordinary general shareholders meeting
April 19, 2011
Notice of Annual General Shareholders Meeting 2011
2010
December 20, 2010
Notice of Extraordinary General Meeting
November 4, 2010
Resolution by the " Commisión Nacional de la Competencia"
November 2, 2010
Clarification on press releases published in certain media
September 30, 2010
Shareholders' commitment to the proposed acquisition of Talecris
July 20, 2010
Grifols obtains its first crédit rating from Standard & Poor's and Moody's
June 23, 2010
Final dividend 2009
June 10, 2010
Voting agreement - amendment
June 10, 2010
Agreement and Plan of Merger among Grifols and Talecris Biotherapeutics Holdings Corp
June 7, 2010
Acquisition Announcement of Talecris Biotherapeutics Holdings Corp
June 7, 2010
Conference call details
May 18, 2010
Notice of Annual General Meeting
January 12, 2010
Resignation of Christian Purlow from the Board of Directors
2009
December 14, 2009
Interim Dividend 2009 - Clarification
December 14, 2009
Interim Dividend 2009
November 3, 2009
Change of registered address
October 7, 2009
Grifols completes its USD600 million corporate bond issue in the US
September 29, 2009
Grifols announces corporate debt issuance in USA
May 28, 2009
The shares of Grifols will be traded in the United States through ADRs
May 20, 2009
Announcement on Grifols dividend payment
April 7, 2009
Annual General Meeting Announcement
March 31, 2009
Grifols signs two supply agreements in brazil
2008
October 14, 2008
Flebogamma® DIF receives marketing license in Australia (Spanish Version)
June 13, 2008
The Company announces a dividend payment for June 23, 2008 (Spanish Version)
May 26, 2008
Grifols obtains a syndicated loan totaling 350 million euros (Spanish Version)
May 22, 2008
Annual General Meeting Announcement Addendum (Spanish Version)
May 7, 2008
Annual General Meeting Announcement (Spanish Version)
2007
August 27, 2007
EMEA authorization to distribute Flebogamma DIF® in Europe (Spanish Version)
August 10, 2007
Announcement of transfer of shares (Spanish Version)
June 26, 2007
Announcement on Grifols dividend payment (Spanish Version)
May 14, 2007
Annual General Meeting Announcement (Spanish Version)
Do you want to know more about one of the leading healthcare companies? Here you will find all the information about Grifols and our commitment to improving the health and well-being of people around world.